McDermott Advises Myonex on its Acquisition of Creapharm’s Pharmaceutical Services Business - McDermott Will & Emery

McDermott Advises Myonex on its Acquisition of Creapharm’s Pharmaceutical Services Business

Overview


McDermott Will & Emery advised Myonex, a leading global clinical trial supply company, on its acquisition of Creapharm’s pharmaceutical services business.

This transaction combines capabilities and flexibility to serve pharmaceutical and biotech companies in both clinical and commercial stages, including companies managing Advanced Therapies.

The McDermott team that advised Myonex comprised:

  • Emmanuelle Trombe, partner, Dr. Deniz Tschammler, partner (Frankfurt), Natacha Vasak and Caroline Noyrez, associates, on Corporate aspects
  • Jilali Maazouz, partner, and Naré Arshakyan, associate, on Employment law aspects
  • Sabine Naugès, partner, and Benoit Feroldi, associate, on Regulatory aspects

About McDermott


McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.